skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Speaking at the 2017 Biotech Showcase™ in San Francisco, Gruenenthal CEO Gabriel Baertschi reveals his ambition to grow the company from its current EUR 1.4 billion a year revenues to EUR 2 billion by 2022, launching four new medicines by that date, consolidating its position as a leader in pain therapeutics, while entering new areas. Consequently, he was at the meeting seeking new opportunities in indications adjacent to pain including inflammation, arthritis, gout, as well as Parkinson’s disease and rare diseases such as Duchenne muscular dystrophy. Looking at both early stage preclinical projects and later stage clinical assets, Baertschi is keen to expand the company’s global footprint. Already with a significant presence in Europe and Latin America, the company wants to expand in the US while entering the Japanese market for the first time



Read also


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: